Rasimcan Meral

741 total citations
23 papers, 373 citations indexed

About

Rasimcan Meral is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Rasimcan Meral has authored 23 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Oncology. Recurrent topics in Rasimcan Meral's work include Nuclear Structure and Function (16 papers), Diabetes and associated disorders (8 papers) and PARP inhibition in cancer therapy (5 papers). Rasimcan Meral is often cited by papers focused on Nuclear Structure and Function (16 papers), Diabetes and associated disorders (8 papers) and PARP inhibition in cancer therapy (5 papers). Rasimcan Meral collaborates with scholars based in United States, Türkiye and Australia. Rasimcan Meral's co-authors include Elif A Oral, Barış Akıncı, Adam Neidert, Jeffrey W. Innis, Jeffrey F. Horowitz, Marwan K. Tayeh, Thomas L. Chenevert, M. Bishr Omary, Graham F. Brady and Barbara J. McKenna and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Rasimcan Meral

21 papers receiving 370 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rasimcan Meral United States 12 224 106 88 53 48 23 373
Christine Yu United States 7 227 1.0× 74 0.7× 101 1.1× 85 1.6× 19 0.4× 13 401
Beth S. Sutton United States 11 72 0.3× 66 0.6× 81 0.9× 108 2.0× 54 1.1× 17 319
Louise Ambye Denmark 12 183 0.8× 164 1.5× 60 0.7× 28 0.5× 168 3.5× 17 517
Yanina Nersesova United States 2 77 0.3× 75 0.7× 141 1.6× 233 4.4× 31 0.6× 2 402
Annamaria Ciccarone Italy 10 78 0.3× 29 0.3× 85 1.0× 35 0.7× 54 1.1× 16 249
Goran Cvijović Serbia 10 67 0.3× 30 0.3× 43 0.5× 37 0.7× 33 0.7× 30 332
Meriem Ouni Germany 12 207 0.9× 71 0.7× 107 1.2× 57 1.1× 57 1.2× 23 382
G Fine United States 9 141 0.6× 54 0.5× 71 0.8× 55 1.0× 48 1.0× 12 311
Eiji Takeshita Japan 11 56 0.3× 51 0.5× 72 0.8× 184 3.5× 106 2.2× 63 402
Lukas Schwake Germany 7 77 0.3× 71 0.7× 31 0.4× 37 0.7× 44 0.9× 12 345

Countries citing papers authored by Rasimcan Meral

Since Specialization
Citations

This map shows the geographic impact of Rasimcan Meral's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rasimcan Meral with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rasimcan Meral more than expected).

Fields of papers citing papers by Rasimcan Meral

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rasimcan Meral. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rasimcan Meral. The network helps show where Rasimcan Meral may publish in the future.

Co-authorship network of co-authors of Rasimcan Meral

This figure shows the co-authorship network connecting the top 25 collaborators of Rasimcan Meral. A scholar is included among the top collaborators of Rasimcan Meral based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rasimcan Meral. Rasimcan Meral is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meral, Rasimcan, Maria Cristina Foss‐Freitas, David T. Broome, et al.. (2025). Metabolic Improvements With Tirzepatide in Lipodystrophy: A Novel Option?. Diabetes Care. 48(5). 756–762. 2 indexed citations
2.
Akıncı, Barış, Nevin Ajluni, Rasimcan Meral, et al.. (2025). Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response. Journal of the Endocrine Society. 9(8). bvaf067–bvaf067.
3.
Meral, Rasimcan, et al.. (2024). RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish population. BMC Cancer. 24(1). 1273–1273. 1 indexed citations
4.
Foss‐Freitas, Maria Cristina, Rasimcan Meral, Adam Neidert, et al.. (2023). A Very-Low-Calorie Diet Can Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in Familial Partial Lipodystrophy. Obesity Facts. 17(1). 103–108. 4 indexed citations
5.
Çalışkan, Yaşar, Erol Demir, Egemen Cebeci, et al.. (2022). COSMC expression as a predictor of remission in IgA nephropathy. International Urology and Nephrology. 55(4). 1033–1044. 2 indexed citations
6.
Akıncı, Barış, André Monteiro da Rocha, Rasimcan Meral, et al.. (2021). Cardiac phenotype in familial partial lipodystrophy. Clinical Endocrinology. 94(6). 1043–1053. 14 indexed citations
7.
Akıncı, Barış, Angela Subauste, Nevin Ajluni, et al.. (2021). Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med. 2(7). 814–835.e6. 19 indexed citations
8.
Foss‐Freitas, Maria Cristina, Rasimcan Meral, Muhammet Özer, et al.. (2021). The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe Obesity. Obesity. 29(2). 274–278. 12 indexed citations
9.
Meral, Rasimcan. (2020). Chronic ACE Inhibitor use is Associated with Decreased Odds of Severe Disease in Patients with COVID-19. The Anatolian Journal of Cardiology. 24(1). 21–29. 34 indexed citations
10.
Akıncı, Barış, Rasimcan Meral, Rita Hench, et al.. (2020). The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide. Endocrinology Diabetes and Metabolism Case Reports. 2020. 10 indexed citations
11.
Affinati, Alison H., Rasimcan Meral, Kelly Walkovich, et al.. (2019). Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. SHILAP Revista de lepidopterología. 5(1). 9–9. 12 indexed citations
12.
Esfandiari, Nazanene H., Melvyn Rubenfire, Adam Neidert, et al.. (2019). Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. SHILAP Revista de lepidopterología. 5(1). 4–4. 7 indexed citations
13.
Akıncı, Barış, Rasimcan Meral, Rita Hench, et al.. (2019). MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data. Journal of the Endocrine Society. 3(Supplement_1). 2 indexed citations
14.
Meral, Rasimcan, et al.. (2019). MON-104 Defining the Contribution of Weight to the Extent of Metabolic Disease in FPLD: Insights from a Retrospective "Matched" Case-Control Study. Journal of the Endocrine Society. 3(Supplement_1). 2 indexed citations
15.
Esfandiari, Nazanene H., Yingying Luo, Angela Subauste, et al.. (2018). Metabolic Parameters, Weight Loss, and Comorbidities 4 Years After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Obesity Surgery. 28(11). 3415–3423. 31 indexed citations
16.
Sahinoz, Melis, Graham F. Brady, Rasimcan Meral, et al.. (2018). Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. SHILAP Revista de lepidopterología. 4(1). 6–6. 11 indexed citations
17.
Akıncı, Barış, Rasimcan Meral, & Elif A Oral. (2018). Update on Therapeutic Options in Lipodystrophy. Current Diabetes Reports. 18(12). 139–139. 25 indexed citations
18.
Akıncı, Barış, Rasimcan Meral, & Elif A Oral. (2018). Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities. Current Diabetes Reports. 18(12). 143–143. 71 indexed citations
19.
Meral, Rasimcan, Benjamin J. Ryan, Noemi Malandrino, et al.. (2018). “Fat Shadows” From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. Diabetes Care. 41(10). 2255–2258. 29 indexed citations
20.
Ajluni, Nevin, Rasimcan Meral, Adam Neidert, et al.. (2017). Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clinical Endocrinology. 86(5). 698–707. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christine Yu Breakdown of academic impact, for papers by Beth S. Sutton Breakdown of academic impact, for papers by Louise Ambye Breakdown of academic impact, for papers by Yanina Nersesova Breakdown of academic impact, for papers by Annamaria Ciccarone Breakdown of academic impact, for papers by Goran Cvijović Breakdown of academic impact, for papers by Meriem Ouni Breakdown of academic impact, for papers by G Fine Breakdown of academic impact, for papers by Eiji Takeshita Breakdown of academic impact, for papers by Lukas Schwake
Rankless by CCL
2026